GlassScriptPhysician profile
Mekdes Ditamo
NPI 1639584709
$2,327.10
in general payments reported to CMS, 2019-2025
21 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $604 · 2022: $507 · 2023: $840 · 2024: $205 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $375.09 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $320.90 | 2021-2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $196.93 | 2023-2025 | Ultomiris, Soliris |
| Genzyme Corporation | $189.77 | 2022-2023 | |
| Horizon Therapeutics Plc | $183.71 | 2021-2023 | Uplizna |
| Grifols USA, LLC | $164.48 | 2023 | Gamunex-C |
| Abbvie INC. | $157.03 | 2022-2025 | Botox |
| Catalyst Pharmaceuticals, INC. | $122.63 | 2021 | |
| Genentech USA, INC. | $118.22 | 2021 | |
| Biogen, INC. | $114.84 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $111.19 | 2022 | |
| Banner Life Sciences, LLC | $63.49 | 2022-2023 | |
| Sk Life Science, INC. | $43.00 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $29.33 | 2022 | |
| Neurelis, INC. | $27.85 | 2024 | Valtoco |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $22.70 | 2023 | Purified Cortrophin Gel |
| Sumitomo Pharma America, INC. | $20.29 | 2023 | Aptiom |
| Axsome Therapeutics, INC. | $19.86 | 2024 | Sunosi |
| Pfizer INC. | $18.54 | 2023 | |
| Sandoz INC. | $14.03 | 2023 | |
| Amgen INC. | $13.22 | 2024 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mekdes Ditamo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.